Find, compare & contact
Dichlororibofuranosylbenzimidazole
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Dichlororibofuranosylbenzimidazole API 53-85-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Dichlororibofuranosylbenzimidazole. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Dichlororibofuranosylbenzimidazole
- Synonyms:
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- Cas Number:
- 53-85-0
- DrugBank number:
- DB08473
- Unique Ingredient Identifier:
- 8153319T3Q
General Description:
Dichlororibofuranosylbenzimidazole is a chemical compound identified by the CAS number 53-85-0. It is known for its distinct pharmacological properties and applications.
Classification:
Dichlororibofuranosylbenzimidazole belongs to the class of organic compounds known as benzimidazole ribonucleosides and ribonucleotides. These are nucleosides with a structure that consists of an imidazole moiety of benzimidazole is N-linked to a ribose (or deoxyribose). Nucleotides have a phosphate group linked to the C5 carbon of the ribose (or deoxyribose) moiety, classified under the direct parent group Benzimidazole ribonucleosides and ribonucleotides. This compound is a part of the Organic compounds, falling under the Nucleosides, nucleotides, and analogues superclass, and categorized within the Benzimidazole ribonucleosides and ribonucleotides class, specifically within the None subclass.
Categories:
Dichlororibofuranosylbenzimidazole is categorized under the following therapeutic classes: Enzyme Inhibitors, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Ribonucleosides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Dichlororibofuranosylbenzimidazole is a type of Enzyme Replacements/modifiers
Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.
Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.
On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.
Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.
The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.
Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.
